 Lingering inflammation after heart attack can lead heart failure. It can also claim another victim -- the kidneys. New research shows that a bioactive compound called resolvin D-1, injected as a therapeutic dose, is able to limit this collateral damage in the kidneys, as tested in an animal model.
Lingering inflammation after heart attack can lead heart failure. It can also claim another victim -- the kidneys. New research shows that a bioactive compound called resolvin D-1, injected as a therapeutic dose, is able to limit this collateral damage in the kidneys, as tested in an animal model.By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/